Innovative TB medical products are needed in low-incidence and high-incidence countries alike to support patient-centered care for TB patients and advance toward global TB elimination. If world leaders are serious about the commitments made to ending the global TB epidemic at the UN High-level Meeting in September 2018, investments in TB R&D must match the rhetoric.